title: [Expression of CD147, matrix metalloproteinases and transforming growth factor beta1 in breast cancer].
abstract: OBJECTIVE
  To investigate the expression of CD147, matrix metalloproteinase (MMP)-2, MMP-9, Transforming growth factor (TGFbeta1) and TGFbetaRI proteins and their relationships to breast cancer.
  
  
  METHODS
  The expression of CD147, MMP-2, MMP-9, TGFbeta1 and TGFbetaRI proteins was examined on tissue chips containing 160 cases of breast carcinomas by S-P immunohistochemical method.
  
  
  RESULTS
  The positive rates of CD147, MMP-2, MMP-9, TGFbeta1 and TGFbetaRI proteins were 87.5% (140/160), 96.9% (155/160), 95.0% (152/160), 73.7% (118/160) and 60.6% (97/160), respectively. The expression of CD147 was positively correlated with axillary lymph node metastasis, TNM staging and HER2 over expression (P < 0.01, P < 0.05 and P < 0.01, respectively), and inversely correlated with PR expression (P < 0.05). The patients' relapse-free survival was shorter in TGFbeta1-positive group than in TGFbeta1 negative group (P < 0.05). Both the expression of MMP-2 and MMP-9 were positively correlated with CD147 expression; and both the expression of TGFbeta1 and TGFbetaRI were positively correlated with CD147 expression (P < 0.01 and P < 0.05, respectively).
  
  
  CONCLUSIONS
  The expression of CD147 is considered closely correlated with tumor invasion, metastasis and prognosis in breast cancer, and has also a close correlation with MMP-2, MMP-9, TGFbeta1 and TGFbetaRI expression.
authors.affiliation: Department of Pathology, Anhui Medical University, Hefei 230032, China.
authors.forename: Song
authors.initials: S
authors.lastname: Xue
authors.forename: Shou-xin
authors.initials: SX
authors.lastname: Li
authors.forename: Zheng-sheng
authors.initials: ZS
authors.lastname: Wu
authors.forename: Xiao-nan
authors.initials: XN
authors.lastname: Wang
authors.forename: Qiang
authors.initials: Q
authors.lastname: Wu
authors.forename: Feng
authors.initials: F
authors.lastname: Yang
mesh_terms: D000328:Adult; D000368:Aged; D051926:Basigin / Q000378:metabolism*; D001943:Breast Neoplasms / Q000378:metabolism* / Q000473:pathology; D018270:Carcinoma, Ductal, Breast / Q000378:metabolism* / Q000473:pathology; D005260:Female; D018226:Fibroadenoma / Q000378:metabolism / Q000473:pathology; D005500:Follow-Up Studies; D006801:Humans; D008207:Lymphatic Metastasis; D020778:Matrix Metalloproteinase 2 / Q000378:metabolism*; D020780:Matrix Metalloproteinase 9 / Q000378:metabolism*; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D017346:Protein Serine-Threonine Kinases / Q000378:metabolism; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D000077293:Receptor, Transforming Growth Factor-beta Type I; D011980:Receptors, Progesterone / Q000378:metabolism; D018125:Receptors, Transforming Growth Factor beta / Q000378:metabolism; D015996:Survival Rate; D053773:Transforming Growth Factor beta1 / Q000378:metabolism*; D055815:Young Adult
chemical_list: D051926:Basigin; D020778:Matrix Metalloproteinase 2; D020780:Matrix Metalloproteinase 9; D017346:Protein Serine-Threonine Kinases; D018719:Erb-b2 Receptor Tyrosine Kinases; D000077293:Receptor, Transforming Growth Factor-beta Type I; D011980:Receptors, Progesterone; D018125:Receptors, Transforming Growth Factor beta; D053773:Transforming Growth Factor beta1; C522361:MMP2 protein, human